AbbVie Inc. Indefinite-lived Intangible Assets (Excluding Goodwill), Fair Value Disclosure
AbbVie Inc. (ABBV) had Indefinite-lived Intangible Assets (Excluding Goodwill), Fair Value Disclosure of $2.40 billion as of 2024-11-11, per its 10-K filed 2026-02-20.
Financial Statements › Notes › Fair Value Disclosures › Fair Value, Net Asset (Liability)
us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure · last filed 2026-02-20
- 2024-11-11: Indefinite-lived Intangible Assets (Excluding Goodwill), Fair Value Disclosure $2.40B; Indefinite-lived Intangible Assets (Excluding Goodwill), Fair Value Disclosure as first filed $6.90B.
| Period end | Indefinite-lived Intangible Assets (Excluding Goodwill), Fair Value Disclosure | Indefinite-lived Intangible Assets (Excluding Goodwill), Fair Value Disclosure as first filed |
|---|---|---|
| 2024-11-11 | $2.40B 10-K · filed 2026-02-20 | $6.90B 10-K · filed 2025-02-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |